PRVB - プロベンション・バイオ (Provention Bio Inc.)

PRVBのニュース

   Provention Bio to Report First Quarter 2022 Financial Results on May 5, 2022  2022/04/28 11:30:00 PR Newswire
RED BANK, N.J., April 28, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022, before…
   Analysts Predict An Provention Bio Inc. (NASDAQ: PRVB) Spike?  2022/04/23 11:30:00 Stocks Register
Provention Bio Inc. (NASDAQ:PRVB) shares, rose in value on Friday, 04/22/22, with the stock price up by 0.53% to the previous day’s close as strong demand from buyers drove the stock to $5.64. Actively observing the price movement in the last trading, the stock closed the session at $5.61, falling within a range of $5.47 … Analysts Predict An Provention Bio Inc. (NASDAQ: PRVB) Spike? Read More »
   Provention Bio (PRVB): BLA Accepted; Downgrading To A Hold  2022/03/31 20:35:58 Seeking Alpha
   Provention Bio''s Coxsackievirus Vaccine Candidate Elicits Durable Virus-Neutralizing Antibodies At Six Months  2022/03/28 19:27:06 Benzinga
Provention Bio Inc (NASDAQ: PRVB ) announced results from the final analysis of its first-in-human PROVENT study of PRV-101, a polyvalent inactivated coxsackievirus B (CVB) vaccine candidate. Provention is developing PRV-101 for the prevention of acute CVB infection and its complications and the potential … Full story available on Benzinga.com
   PRVB stock rises on FDA acceptance of marketing application for diabetes therapy (PRVB)  2022/03/21 12:43:17 Seeking Alpha
Clinical stage biopharmaceutical company, Provention Bio (PRVB), announced on Monday that the U.S
   Provention Bio, Inc''s. (PRVB) CEO Ashleigh Palmer on Q4 2021 Results - Earnings Call Transcript  2022/02/24 19:56:05 Seeking Alpha
   Provention Bio Q4 2021 Earnings Preview (NASDAQ:PRVB)  2022/02/23 17:07:20 Seeking Alpha
Provention Bio (NASDAQ:PRVB) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is -$0.46 (+20.7% Y/Y) and the
   Provention Bio resubmits marketing application for diabetes drug in U.S.  2022/02/22 14:22:10 Seeking Alpha
The clinical-stage biopharmaceutical company, Provention Bio (PRVB), is trading ~5% higher in the pre-market after the company announced the resubmission of its marketing application
   Provention Bio Inc. (NASDAQ: PRVB) Is Up 51.05% In A Month. Could There Be Any Hope That It Will Rise Soon?  2022/02/19 19:00:00 Marketing Sentinel
During the last session, Provention Bio Inc. (NASDAQ:PRVB)s traded shares were 0.5 million, with the beta value of the company hitting 2.64. At the end of the trading day, the stocks price was $6.48, reflecting an intraday loss of -3.14% or -$0.21. The 52-week high for the PRVB share is $15.98, that puts it down Provention Bio Inc. (NASDAQ: PRVB) Is Up 51.05% In A Month. Could There Be Any Hope That It Will Rise Soon? Read More »
   Provention Bio to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022  2022/02/17 21:05:00 PR Newswire
RED BANK, N.J., Feb. 17, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its fourth quarter and full year 2021 financial results on Thursday,…
   Why Provention Bio Stock Skyrocketed Today  2022/01/31 21:13:11 The Motley Fool
The momentum from the company''s good news last week is continuing this week.
   ARVL, RMO and PRVB among mid-day movers  2022/01/31 17:41:41 Seeking Alpha
Gainers: Knightscope KSCP +37%.Bassett Furniture Industries BSET +32%.Inspira Technologies IINN +31%.Provention Bio (PRVB) +30%.Arrival (ARVL) +29%.Yoshitsu TKLF +25%.Singularity
   Provention Bio up 16% after saying it will resubmit teplizumab BLA for type 1 diabetes  2022/01/27 22:40:13 Seeking Alpha
Shares of Provention have shot up 16% in after-hours trading after announcing its will resubmit a Biologics License Application for teplizumab for type 1 diabetes.
   Provention Bio initiates mid-stage study of lupus candidate PRV-3279  2022/01/20 22:13:17 Seeking Alpha
Provention Bio has begun a phase 2a study of PRV-3279, its candidate for systemic lupus erythematosus.
   Lawson Products, Houghton Mifflin Harcourt lead postmarket gainers; Rhythm Pharma top...  2022/01/14 22:04:41 Seeking Alpha
Gainers: Lawson Products (LAWS) +7%, Houghton Mifflin Harcourt HMHC +5%, Provention Bio (PRVB) +3%, Array Technologies (ARRY) +3%, People''s United Financial (PBCT) +2%.Losers:

calendar